Cumberland Pharmaceuticals (CPIX) Cash & Equivalents (2010 - 2026)

Cumberland Pharmaceuticals (CPIX) has 17 years of Cash & Equivalents data on file, last reported at $11.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 27.14% year-over-year to $11.0 million; the trailing twelve-month figure through Mar 2026 stood at $11.0 million (down 27.14% YoY), and the FY2025 full-year result was $11.4 million, down 36.29% from the prior year.
• Cash & Equivalents eased to $11.0 million in Q1 2026, from $11.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $19.8 million in Q4 2022 to a low of $11.0 million in Q1 2026.
• A 5-year average of $16.8 million and a median of $17.5 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents grew 13.2% in 2024 and slumped 36.29% in 2025, its largest moves.
• Tracing CPIX's Cash & Equivalents over 5 years: stood at $19.8 million in 2022, then slipped by 7.27% to $18.3 million in 2023, then dropped by 1.95% to $18.0 million in 2024, then tumbled by 36.29% to $11.4 million in 2025, then slipped by 3.82% to $11.0 million in 2026.
• Business Quant data shows CPIX's Cash & Equivalents at $11.0 million in Q1 2026, $11.4 million in Q4 2025, and $15.2 million in Q3 2025.